129 related articles for article (PubMed ID: 38036098)
1. EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
Peptides; 2024 May; 175():171111. PubMed ID: 38036098
[TBL] [Abstract][Full Text] [Related]
2. Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.
Sokkar P; Harms M; Stürzel C; Gilg A; Kizilsavas G; Raasholm M; Preising N; Wagner M; Kirchhoff F; Ständker L; Weidinger G; Mayer B; Münch J; Sanchez-Garcia E
Commun Biol; 2021 Sep; 4(1):1113. PubMed ID: 34552197
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.
Zirafi O; Hermann PC; Münch J
J Leukoc Biol; 2016 Jun; 99(6):863-8. PubMed ID: 26965637
[TBL] [Abstract][Full Text] [Related]
4. Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.
Rodríguez-Alfonso A; Heck A; Ruiz-Blanco YB; Gilg A; Ständker L; Kuan SL; Weil T; Sanchez-Garcia E; Wiese S; Münch J; Harms M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499357
[TBL] [Abstract][Full Text] [Related]
5. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.
Hatse S; Bridger G; de Clercq E; Schols D
Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL443-52. PubMed ID: 14995074
[TBL] [Abstract][Full Text] [Related]
6. Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.
Kaiser LM; Harms M; Sauter D; Rawat VPS; Glitscher M; Hildt E; Tews D; Hunter Z; Münch J; Buske C
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669329
[TBL] [Abstract][Full Text] [Related]
7. An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.
Harms M; Habib MMW; Nemska S; Nicolò A; Gilg A; Preising N; Sokkar P; Carmignani S; Raasholm M; Weidinger G; Kizilsavas G; Wagner M; Ständker L; Abadi AH; Jumaa H; Kirchhoff F; Frossard N; Sanchez-Garcia E; Münch J
Acta Pharm Sin B; 2021 Sep; 11(9):2694-2708. PubMed ID: 34589390
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of an endogenous CXCR4 antagonist.
Zirafi O; Kim KA; Ständker L; Mohr KB; Sauter D; Heigele A; Kluge SF; Wiercinska E; Chudziak D; Richter R; Moepps B; Gierschik P; Vas V; Geiger H; Lamla M; Weil T; Burster T; Zgraja A; Daubeuf F; Frossard N; Hachet-Haas M; Heunisch F; Reichetzeder C; Galzi JL; Pérez-Castells J; Canales-Mayordomo A; Jiménez-Barbero J; Giménez-Gallego G; Schneider M; Shorter J; Telenti A; Hocher B; Forssmann WG; Bonig H; Kirchhoff F; Münch J
Cell Rep; 2015 May; 11(5):737-47. PubMed ID: 25921529
[TBL] [Abstract][Full Text] [Related]
9. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
10. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
Gilg A; Harms M; Olari LR; Urbanowitz AK; Bonig H; Münch J
J Transl Med; 2021 May; 19(1):190. PubMed ID: 33941197
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
12. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer.
Xu Q; Wang Z; Chen X; Duan W; Lei J; Zong L; Li X; Sheng L; Ma J; Han L; Li W; Zhang L; Guo K; Ma Z; Wu Z; Wu E; Ma Q
Oncotarget; 2015 Mar; 6(7):4717-32. PubMed ID: 25605248
[TBL] [Abstract][Full Text] [Related]
13. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
14. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4.
Marchesi F; Monti P; Leone BE; Zerbi A; Vecchi A; Piemonti L; Mantovani A; Allavena P
Cancer Res; 2004 Nov; 64(22):8420-7. PubMed ID: 15548713
[TBL] [Abstract][Full Text] [Related]
15. CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells.
Shen B; Zheng MQ; Lu JW; Jiang Q; Wang TH; Huang XE
Asian Pac J Cancer Prev; 2013; 14(9):5403-8. PubMed ID: 24175834
[TBL] [Abstract][Full Text] [Related]
16. Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.
Harms M; Fabech Hansson R; Gilg A; Almeida-Hernández Y; Löffler J; Rodríguez-Alfonso A; Habib MMW; Albers D; Ahmed NS; Abadi AH; Winter G; Rasche V; Beer AJ; Weidinger G; Preising N; Ständker L; Wiese S; Sanchez-Garcia E; Zelikin AN; Münch J
J Med Chem; 2023 Nov; 66(22):15189-15204. PubMed ID: 37940118
[TBL] [Abstract][Full Text] [Related]
17. Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.
Jung CK; Münch J; Jacob T
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003419
[TBL] [Abstract][Full Text] [Related]
18. The
Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
[TBL] [Abstract][Full Text] [Related]
19. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
20. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]